Vivani Medical (VANI) announced that its board of directors has set the record date for the approved spin-off of Cortigent (CRGT), its wholly-owned subsidiary developing brain implant devices with cutting-edge neuromodulation technology. Vivani shareholders holding common stock as of the record date, October 8, 2025, will receive common stock in Cortigent. Cortigent is expected to trade on the Nasdaq Stock Market under the ticker symbol “CRGT” subject to regulatory approvals and other conditions. The distribution date and share dividend ratio will be announced at a later date.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VANI:
- Vivani Medical Shares Insights at Industry Conferences
- Vivani Medical Announces Phase 1 Study for Semaglutide Implant
- Vivani Medical provides update on plans for NPM-139 semaglutide implant
- Vivani Medical’s Promising Future: Buy Rating Backed by Financial Stability and Innovative Projects
- Vivani Medical’s Strategic Focus and Promising Developments Drive Buy Rating